Genelux Corp. (GNLX) Price & Analysis

Compare

283 Followers

GNLX Stock Chart & Stats

$4.64

-$0.06(-2.24%)

At close: Jan 08 4:00 PM EST

$4.64

-$0.06(-2.24%)

Day’s Range― - ―

52-Week Range$1.99 - $8.54

Previous CloseN/A

Volume23.79K

Average Volume (3M)156.94K

Market Cap

$306.34M

Enterprise Value$82.64M

Total Cash (Recent Filing)$20.91M

Total Debt (Recent Filing)$1.62M

Price to Earnings (P/E)―

Beta0.77

Next Earnings

Apr 06, 2026

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding37,773,440

10 Day Avg. Volume178,540

30 Day Avg. Volume156,945

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)2.82

Price to Sales (P/S)9277.96

P/FCF Ratio-3.43

Enterprise Value/Market Cap0.27

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-577.90

Enterprise Value/Ebitda-2.62

Forecast

1Y Price Target

$22.50

Price Target Upside384.91% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe ongoing pivotal Phase 3 trial in platinum-resistant/refractory ovarian cancer is supported by positive prior Phase 2 data, partially de-risking the ongoing study.

Pipeline DevelopmentGenelux reported progress across its pipeline of Olvi-Vec trials.

Product DifferentiationOlvi-Vec is viewed as a potentially best-in-class oncolytic virus, differentiated by its vaccinia backbone, known for broad immune activation and dual delivery options.

Bears Say

Financial PerformanceThe company reported a net loss of ($7.9M) and ended the period with $21.0M in cash and short-term investments on the balance sheet.

Treatment EfficacyPatients receiving Olvi-Vec for recurrent NSCLC have already progressed on CPIs, indicating a lower expected efficacy for these patients.

Genelux Corp. News

Genelux Corp’s Promising Oncolytic Virus Advancements and Market Potential Drive Buy Rating

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Genelux Corp., with...

1M ago

GNLX

Promising Clinical Developments in Genelux Corp.’s Olvi-Vec Trials Support Buy Rating

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Genelux Corp. today and set a price target...

1M ago

GNLX

Genelux reports Q3 EPS (21c), consensus (21c)

“In the third quarter, we continued to progress Olvi-Vec’s development across multiple solid tumor indications, positioning the program...

1M ago

GNLX

Genelux initiated with a Buy at Titan Partners

Titan Partners analyst Boris Peaker initiated coverage of Genelux (GNLX) with a Buy rating and $20 price target...

1M ago

GNLX

Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment

Genelux Corp. (($GNLX)) announced an update on their ongoing clinical study. The OnPrime study, officially titled ‘A Randomized...

1M ago

GNLX

Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment

Genelux Corp. (($GNLX)) announced an update on their ongoing clinical study. Genelux Corp. is currently conducting a Phase...

1M ago

GNLX

Genelux Corp: Strong Buy Rating Backed by Promising Olvi-Vec Developments and Sector Momentum

Maxim Group analyst Jason McCarthy has maintained their bullish stance on GNLX stock, giving a Buy rating yesterday....

2M ago

GNLX

Genelux price target raised to $20 from $10 at Maxim

Maxim raised the firm’s price target on Genelux (GNLX) to $20 from $10 and keeps a Buy rating...

2M ago

GNLX

REPL

Genelux initiated with a Buy at Lake Street

Lake Street analyst Chad Messer initiated coverage of Genelux (GNLX) with a Buy rating and $16 price target...

2M ago

GNLX

Genelux Corp. Lowers Stock Option Exercise Prices

Genelux Corp. ( ($GNLX) ) just unveiled an update. On September 1, 2025, Genelux Corporation’s Board of Directors...

3M ago

GNLX

Genelux Corp.’s Innovative Cancer Treatment Approach Earns Buy Rating

Bruce Jackson, an analyst from Benchmark Co., maintained the Buy rating on Genelux Corp.. The associated price target...

4M ago

GNLX

Promising Outlook for Genelux Corp. with Olvi-Vec Advancements and Strong Financial Position

Maxim Group analyst Jason McCarthy has maintained their bullish stance on GNLX stock, giving a Buy rating yesterday....

4M ago

GNLX

Promising Potential of Genelux Corp.’s Olvi-Vec in Oncology: A Buy Rating Based on Clinical Data and Strategic Developments

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Genelux Corp., retaining the price target of...

4M ago

GNLX

Genelux reports Q2 EPS (20c), consensus (22c)

“With important data milestones on the horizon, Olvi-Vec holds the potential to redefine the treatment paradigms of recurrent...

4M ago

GNLX

GNLX FAQ

What was Genelux Corp.’s price range in the past 12 months?

Genelux Corp. lowest stock price was $1.99 and its highest was $8.54 in the past 12 months.

What is Genelux Corp.’s market cap?

Genelux Corp.’s market cap is $306.34M.

When is Genelux Corp.’s upcoming earnings report date?

Genelux Corp.’s upcoming earnings report date is Apr 06, 2026 which is in 119 days.

How were Genelux Corp.’s earnings last quarter?

Genelux Corp. released its earnings results on Nov 05, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.213 by $0.003.

Is Genelux Corp. overvalued?

According to Wall Street analysts Genelux Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Genelux Corp. pay dividends?

Genelux Corp. does not currently pay dividends.

What is Genelux Corp.’s EPS estimate?

Genelux Corp.’s EPS estimate is -0.22.

How many shares outstanding does Genelux Corp. have?

Genelux Corp. has 37,773,440 shares outstanding.

What happened to Genelux Corp.’s price movement after its last earnings report?

Genelux Corp. reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.213. Following the earnings report the stock price went down -32.398%.

Which hedge fund is a major shareholder of Genelux Corp.?

Currently, no hedge funds are holding shares in GNLX

Genelux Corp. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-98.72%

Trailing 12-Months

Asset Growth

-28.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genelux Corp.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Genelux Corp. (GNLX) Earnings & Revenues

Historic Earnings Reports

GNLX Stock 12 Month Forecast

Average Price Target

$22.50

▲(384.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","32":"$32","8.75":"$8.75","16.5":"$16.5","24.25":"$24.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.75,16.5,24.25,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.9,6.907692307692308,8.915384615384616,10.923076923076923,12.930769230769231,14.938461538461539,16.946153846153848,18.953846153846154,20.96153846153846,22.96923076923077,24.97692307692308,26.98461538461538,28.99230769230769,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.9,6.253846153846155,7.607692307692308,8.961538461538462,10.315384615384616,11.66923076923077,13.023076923076923,14.376923076923077,15.730769230769232,17.084615384615386,18.43846153846154,19.792307692307695,21.146153846153844,{"y":22.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.9,5.753846153846154,6.607692307692308,7.461538461538462,8.315384615384616,9.169230769230769,10.023076923076923,10.876923076923077,11.73076923076923,12.584615384615384,13.438461538461539,14.292307692307693,15.146153846153846,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >